Axogen, Inc. (AXGN)
| Market Cap | 813.10M |
| Revenue (ttm) | 119.08M |
| Net Income (ttm) | -22.25M |
| Shares Out | 41.00M |
| EPS (ttm) | -0.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $20.20 |
| Previous Close | $20.06 |
| Change ($) | 0.14 |
| Change (%) | 0.70% |
| Day's Open | 20.18 |
| Day's Range | 20.01 - 20.43 |
| Day's Volume | 56,584 |
| 52-Week Range | 10.42 - 23.94 |
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALACHUA, Fla. and TAMPA, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to per...
Global leader brings 30+ years of biopharma experience to Axogen, Inc. Board of Directors Global leader brings 30+ years of biopharma experience to Axogen, Inc. Board of Directors
ALACHUA, Fla. and TAMPA, Fla., July 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to perip...
Axogen Inc (NASDAQ: AXGN) has announced to suspend the market availability of Avive Soft Tissue Membrane (Avive) effective June 1, pending ongoing discussions with the FDA regarding the regulatory class...
ALACHUA, Fla. and TAMPA, Fla., May 18, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peri...
AxoGen (AXGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ALACHUA, Fla. and TAMPA, Fla. , May 06, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to pe...
AxoGen (AXGN) delivered earnings and revenue surprises of 52.94% and 8.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Axogen (NASDAQ:AXGN) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 57.89% over the past year to ($0.08), which beat...
ALACHUA, Fla. and TAMPA, Fla., May 05, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, toda...
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALACHUA Fla. and TAMPA, Fla., April 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to perip...
ALACHUA, Fla., March 01, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced th...
ALACHUA, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported fina...
ALACHUA, Fla., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, ...
The S&P 500 stocks saw their aggregate trailing 12-month real revenue per share rise at a compound average growth rate (CAGR) of nearly 2% per annum over the past five years. The share price of the benc...
Clinical evidence supporting the company's platform for nerve repair will be featured in several presentations during the scientific sessions Clinical evidence supporting the company's platform for nerv...
ALACHUA, Fla., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, an...
AxoGen: Operating Efficiencies Come Through The P&L And Cash-flow Statement
ALACHUA, Fla., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, to...
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q3 2020 Results - Earnings Call Transcript
AxoGen (AXGN) delivered earnings and revenue surprises of 130.77% and 11.06%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
ALACHUA, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported fina...
ALACHUA, Fla., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, to...
COVID-19 has complicated a sales restructuring effort that was already severely testing the patience of investors, as the company looks to refocus on its core trauma opportunity.
Healthcare veteran brings 30+ years of medtech experience to Axo g en, Inc. Board of Directors
ALACHUA, Fla., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerve...
New data highlights the clinical and economic value of Avance® Nerve Graft compared to nerve autograft New data highlights the clinical and economic value of Avance® Nerve Graft compared to nerve autograft
ALACHUA, Fla., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves...
AxoGen's (AXGN) CEO Karen Zaderej on Q2 2020 Results - Earnings Call Transcript
AxoGen (AXGN) delivered earnings and revenue surprises of 40.00% and 5.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALACHUA, Fla., July 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves...
RECON is a pivotal study supporting the Company’s Biologics License Application (BLA) for Avance® Nerve Graft RECON is a pivotal study supporting the Company’s Biologics License Application (BLA) for Av...
ALACHUA, Fla., July 15, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, ...
ALACHUA, Fla., July 01, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced a...
Freitag will continue as member of board of directors and serve as special counsel in transitional role through October Freitag will continue as member of board of directors and serve as special counsel...
ALACHUA, Fla., May 20, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves,...
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2020 Results - Earnings Call Transcript
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALACHUA, Fla., April 23, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced ...
ALACHUA, Fla., March 02, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerve...
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q4 2019 Results - Earnings Call Transcript
Largest peripheral nerve repair registry in the world generates clinical evidence of repair, safety, and outcomes data for peripheral nerve injuries Largest peripheral nerve repair registry in the world...
AxoGen Working Its Way Out Of The Penalty Box, But Execution Is Key
Company will develop an automated bioprocessing system for human tissue scaffolds
Parade float will highlight the life-changing power of tissue and organ donation Parade float will highlight the life-changing power of tissue and organ donation
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q3 2019 Results - Earnings Call Transcript
AxoGen (AXGN) delivered earnings and revenue surprises of 30.00% and 1.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
About AXGN
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM... [Read more...]
| Industry Medical Devices | |
| Stock Exchange NASDAQ | Ticker Symbol AXGN |
Financial Performance
In 2020, Axogen's revenue was $112.30 million, an increase of 5.24% compared to the previous year's $106.71 million. Losses were -$23.79 million, -18.36% less than in 2019.
Analyst Forecasts
According to 7 analysts, the average rating for Axogen stock is "Buy." The 12-month stock price forecast is 26.17, which is an increase of 29.55% from the latest price.